Details of the Drug

General Information of Drug (ID: DM51TYR)

Drug Name
Esmolol
Synonyms
ASL 8052-001; Brevibloc (TN); Esmolol (INN); Esmolol [INN:BAN]; Methyl p-[2-hydroxy-3-(isopropylamino)propoxy]hydrocinnamate; Methyl p-(2-hydroxy-3-(isopropylamino)propoxy)hydrocinnamate; Methyl 3-[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]propanoate; Methyl 4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)benzenepropanoate; Methyl 3-[4-({2-hydroxy-3-[(1-methylethyl)amino]propyl}oxy)phenyl]propanoate; Methyl 3-{4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl}propanoate; Benzenepropanoic acid, 4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)-, methyl ester; (+-)-Esmolol; (+-)-methyl p-(2-hydroxy-3-(isopropylamino)propoxy)hydrocinnamate
Indication
Disease Entry ICD 11 Status REF
Acute supraventricular tachycardia BC81 Approved [1]
Therapeutic Class
Antihypertensive Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 295.37
Logarithm of the Partition Coefficient (xlogp) 1.9
Rotatable Bond Count (rotbonds) 10
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 5
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [2]
Clearance
The clearance of drug is 20 L/h/kg in Men []
Elimination
0.5% of drug is excreted from urine in the unchanged form [2]
Half-life
The concentration or amount of drug in body reduced by one-half in 3.7 hours [3]
Metabolism
The drug is metabolized via the esterases []
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.67709 micromolar/kg/day [4]
Unbound Fraction
The unbound fraction of drug in plasma is 0.59% [3]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 1.2 L/kg [3]
Water Solubility
The ability of drug to dissolve in water is measured as 20 mg/mL [2]
Chemical Identifiers
Formula
C16H25NO4
IUPAC Name
methyl 3-[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]propanoate
Canonical SMILES
CC(C)NCC(COC1=CC=C(C=C1)CCC(=O)OC)O
InChI
InChI=1S/C16H25NO4/c1-12(2)17-10-14(18)11-21-15-7-4-13(5-8-15)6-9-16(19)20-3/h4-5,7-8,12,14,17-18H,6,9-11H2,1-3H3
InChIKey
AQNDDEOPVVGCPG-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
59768
ChEBI ID
CHEBI:88206
CAS Number
81147-92-4
DrugBank ID
DB00187
TTD ID
D03XTC
VARIDT ID
DR00853
INTEDE ID
DR0626
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Adrenergic receptor beta-1 (ADRB1) TTR6W5O ADRB1_HUMAN Antagonist [5]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 2D6 (CYP2D6)
Main DME 		DECB0K3 CP2D6_HUMAN Substrate [6]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Esmolol (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Bepridil DM0RKS4 Moderate Increased risk of cardiac depression by the combination of Esmolol and Bepridil. Angina pectoris [BA40] [7]
Dronedarone DMA8FS5 Moderate Increased risk of atrioventricular block by the combination of Esmolol and Dronedarone. Angina pectoris [BA40] [8]
Nifedipine DMSVOZT Moderate Increased risk of cardiac depression by the combination of Esmolol and Nifedipine. Angina pectoris [BA40] [7]
Promazine DMZAL7W Moderate Additive hypotensive effects by the combination of Esmolol and Promazine. Appearance/behaviour symptom [MB23] [9]
Cariprazine DMJYDVK Moderate Additive hypotensive effects by the combination of Esmolol and Cariprazine. Bipolar disorder [6A60] [9]
Atracurium DM42HXN Moderate Additive neuromuscular blocking effects by the combination of Esmolol and Atracurium. Corneal disease [9A76-9A78] [10]
Mivacurium DM473VD Moderate Additive neuromuscular blocking effects by the combination of Esmolol and Mivacurium. Corneal disease [9A76-9A78] [10]
Pancuronium DMB0VY8 Moderate Additive neuromuscular blocking effects by the combination of Esmolol and Pancuronium. Corneal disease [9A76-9A78] [10]
Tubocurarine DMBZIVP Moderate Additive neuromuscular blocking effects by the combination of Esmolol and Tubocurarine. Corneal disease [9A76-9A78] [10]
Nimodipine DMQ0RKZ Moderate Increased risk of cardiac depression by the combination of Esmolol and Nimodipine. Coronary vasospastic disease [BA85] [7]
Pasireotide DMHM7JS Moderate Increased risk of bradycardia by the combination of Esmolol and Pasireotide. Cushing syndrome [5A70] [11]
OPC-34712 DMHG57U Moderate Additive hypotensive effects by the combination of Esmolol and OPC-34712. Depression [6A70-6A7Z] [9]
Ethacrynic acid DM60QMR Moderate Increased risk of hyperglycemia by the combination of Esmolol and Ethacrynic acid. Essential hypertension [BA00] [12]
Nicardipine DMCDYW7 Moderate Increased risk of cardiac depression by the combination of Esmolol and Nicardipine. Essential hypertension [BA00] [7]
Phenylephrine DMZHUO5 Moderate Additive hypertensive effects by the combination of Esmolol and Phenylephrine. Faecal incontinence [ME07] [13]
Cimetidine DMH61ZB Moderate Decreased metabolism of Esmolol caused by Cimetidine mediated inhibition of CYP450 enzyme. Gastro-oesophageal reflux disease [DA22] [14]
Prazosin DMCD9YG Moderate Additive hypotensive effects by the combination of Esmolol and Prazosin. Heart failure [BD10-BD1Z] [15]
Chlorothiazide DMLHESP Moderate Increased risk of hyperglycemia by the combination of Esmolol and Chlorothiazide. Heart failure [BD10-BD1Z] [12]
Furosemide DMMQ8ZG Moderate Increased risk of ventricular arrhythmias by the combination of Esmolol and Furosemide. Heart failure [BD10-BD1Z] [12]
Bumetanide DMRV7H0 Moderate Increased risk of hyperglycemia by the combination of Esmolol and Bumetanide. Heart failure [BD10-BD1Z] [12]
Torasemide DMXKJ6C Moderate Increased risk of hyperglycemia by the combination of Esmolol and Torasemide. Heart failure [BD10-BD1Z] [12]
Nisoldipine DM7ISKJ Moderate Increased risk of cardiac depression by the combination of Esmolol and Nisoldipine. Hypertension [BA00-BA04] [7]
Levamlodipine DM92S6N Moderate Increased risk of cardiac depression by the combination of Esmolol and Levamlodipine. Hypertension [BA00-BA04] [7]
Doxazosin DM9PLRH Moderate Additive hypotensive effects by the combination of Esmolol and Doxazosin. Hypertension [BA00-BA04] [15]
Isradipine DMA5XGH Moderate Increased risk of cardiac depression by the combination of Esmolol and Isradipine. Hypertension [BA00-BA04] [7]
Verapamil DMA7PEW Major Increased risk of cardiac depression by the combination of Esmolol and Verapamil. Hypertension [BA00-BA04] [7]
Diltiazem DMAI7ZV Major Increased risk of cardiac depression by the combination of Esmolol and Diltiazem. Hypertension [BA00-BA04] [7]
Amlodipine DMBDAZV Moderate Increased risk of cardiac depression by the combination of Esmolol and Amlodipine. Hypertension [BA00-BA04] [7]
Indapamide DMGN1PW Moderate Increased risk of hypertriglyceridemia by the combination of Esmolol and Indapamide. Hypertension [BA00-BA04] [12]
Trichlormethiazide DMHAQCO Moderate Increased risk of hyperglycemia by the combination of Esmolol and Trichlormethiazide. Hypertension [BA00-BA04] [12]
Felodipine DMOSW35 Moderate Increased risk of cardiac depression by the combination of Esmolol and Felodipine. Hypertension [BA00-BA04] [7]
Clevidipine butyrate DMW4M97 Moderate Increased risk of cardiac depression by the combination of Esmolol and Clevidipine butyrate. Hypertension [BA00-BA04] [7]
Propiomazine DMKY8V1 Moderate Additive hypotensive effects by the combination of Esmolol and Propiomazine. Insomnia [7A00-7A0Z] [9]
ITI-007 DMUQ1DO Moderate Additive hypotensive effects by the combination of Esmolol and ITI-007. Insomnia [7A00-7A0Z] [9]
Thalidomide DM70BU5 Moderate Increased risk of ventricular arrhythmias by the combination of Esmolol and Thalidomide. Multiple myeloma [2A83] [16]
Siponimod DM2R86O Major Increased risk of bradycardia by the combination of Esmolol and Siponimod. Multiple sclerosis [8A40] [16]
Fingolimod DM5JVAN Major Increased risk of bradycardia by the combination of Esmolol and Fingolimod. Multiple sclerosis [8A40] [17]
Ozanimod DMT6AM2 Moderate Increased risk of atrioventricular block by the combination of Esmolol and Ozanimod. Multiple sclerosis [8A40] [18]
Prochlorperazine DM53SRA Moderate Additive hypotensive effects by the combination of Esmolol and Prochlorperazine. Nausea/vomiting [MD90] [9]
Promethazine DM6I5GR Moderate Additive hypotensive effects by the combination of Esmolol and Promethazine. Nausea/vomiting [MD90] [9]
Thiethylperazine DMU3IET Moderate Additive hypotensive effects by the combination of Esmolol and Thiethylperazine. Nausea/vomiting [MD90] [9]
Terazosin DM3JCVS Moderate Additive hypotensive effects by the combination of Esmolol and Terazosin. Prostate hyperplasia [GA90] [15]
Silodosin DMJSBT6 Moderate Additive hypotensive effects by the combination of Esmolol and Silodosin. Prostate hyperplasia [GA90] [15]
Alfuzosin DMZVMKF Moderate Additive hypotensive effects by the combination of Esmolol and Alfuzosin. Prostate hyperplasia [GA90] [15]
Levomepromazine DMIKFEL Moderate Additive hypotensive effects by the combination of Esmolol and Levomepromazine. Psychotic disorder [6A20-6A25] [9]
Fluphenazine DMIT8LX Moderate Additive hypotensive effects by the combination of Esmolol and Fluphenazine. Psychotic disorder [6A20-6A25] [9]
Triflupromazine DMKFQJP Moderate Additive hypotensive effects by the combination of Esmolol and Triflupromazine. Psychotic disorder [6A20-6A25] [9]
Quetiapine DM1N62C Moderate Additive hypotensive effects by the combination of Esmolol and Quetiapine. Schizophrenia [6A20] [9]
Mesoridazine DM2ZGAN Moderate Additive hypotensive effects by the combination of Esmolol and Mesoridazine. Schizophrenia [6A20] [9]
Thioridazine DM35M8J Moderate Additive hypotensive effects by the combination of Esmolol and Thioridazine. Schizophrenia [6A20] [9]
Aripiprazole DM3NUMH Moderate Additive hypotensive effects by the combination of Esmolol and Aripiprazole. Schizophrenia [6A20] [9]
Iloperidone DM6AUFY Moderate Additive hypotensive effects by the combination of Esmolol and Iloperidone. Schizophrenia [6A20] [9]
Paliperidone DM7NPJS Moderate Additive hypotensive effects by the combination of Esmolol and Paliperidone. Schizophrenia [6A20] [9]
Loxapine DM8AI9U Moderate Additive hypotensive effects by the combination of Esmolol and Loxapine. Schizophrenia [6A20] [9]
Haloperidol DM96SE0 Moderate Additive hypotensive effects by the combination of Esmolol and Haloperidol. Schizophrenia [6A20] [9]
Perphenazine DMA4MRX Moderate Additive hypotensive effects by the combination of Esmolol and Perphenazine. Schizophrenia [6A20] [9]
Molindone DMAH70G Moderate Additive hypotensive effects by the combination of Esmolol and Molindone. Schizophrenia [6A20] [9]
Chlorpromazine DMBGZI3 Moderate Additive hypotensive effects by the combination of Esmolol and Chlorpromazine. Schizophrenia [6A20] [9]
Thiothixene DMDINC4 Moderate Additive hypotensive effects by the combination of Esmolol and Thiothixene. Schizophrenia [6A20] [9]
Clozapine DMFC71L Moderate Additive hypotensive effects by the combination of Esmolol and Clozapine. Schizophrenia [6A20] [9]
Trifluoperazine DMKBYWI Moderate Additive hypotensive effects by the combination of Esmolol and Trifluoperazine. Schizophrenia [6A20] [9]
Ziprasidone DMM58JY Moderate Additive hypotensive effects by the combination of Esmolol and Ziprasidone. Schizophrenia [6A20] [9]
Risperidone DMN6DXL Moderate Additive hypotensive effects by the combination of Esmolol and Risperidone. Schizophrenia [6A20] [9]
Olanzapine DMPFN6Y Moderate Additive hypotensive effects by the combination of Esmolol and Olanzapine. Schizophrenia [6A20] [9]
Amisulpride DMSJVAM Moderate Increased risk of ventricular arrhythmias by the combination of Esmolol and Amisulpride. Schizophrenia [6A20] [19]
Asenapine DMSQZE2 Moderate Additive hypotensive effects by the combination of Esmolol and Asenapine. Schizophrenia [6A20] [9]
Succinylcholine DM2ET1M Moderate Additive neuromuscular blocking effects by the combination of Esmolol and Succinylcholine. Tonus and reflex abnormality [MB47] [10]
Pipecuronium DM5F84A Moderate Additive neuromuscular blocking effects by the combination of Esmolol and Pipecuronium. Tonus and reflex abnormality [MB47] [10]
Doxacurium DMKE7L9 Moderate Additive neuromuscular blocking effects by the combination of Esmolol and Doxacurium. Tonus and reflex abnormality [MB47] [10]
Vecuronium DMP0UK2 Moderate Additive neuromuscular blocking effects by the combination of Esmolol and Vecuronium. Tonus and reflex abnormality [MB47] [10]
Cisatracurium DMUZPJ5 Moderate Additive neuromuscular blocking effects by the combination of Esmolol and Cisatracurium. Tonus and reflex abnormality [MB47] [10]
Rocuronium DMY9BMK Moderate Additive neuromuscular blocking effects by the combination of Esmolol and Rocuronium. Tonus and reflex abnormality [MB47] [10]
Methdilazine DMAUHQX Moderate Additive hypotensive effects by the combination of Esmolol and Methdilazine. Vasomotor/allergic rhinitis [CA08] [9]
Trimeprazine DMEMV9D Moderate Additive hypotensive effects by the combination of Esmolol and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [20]
Disopyramide DM5SYZP Major Additive hypotensive effects by the combination of Esmolol and Disopyramide. Ventricular tachyarrhythmia [BC71] [21]
Amiodarone DMUTEX3 Moderate Increased risk of atrioventricular block by the combination of Esmolol and Amiodarone. Ventricular tachyarrhythmia [BC71] [22]
⏷ Show the Full List of 76 DDI Information of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7178).
2 BDDCS applied to over 900 drugs
3 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
5 Beta-1 selective adrenergic antagonist landiolol and esmolol can be safely used in patients with airway hyperreactivity. Heart Lung. 2009 Jan-Feb;38(1):48-55.
6 Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet. 2016 Dec;31(6):425-432.
7 Anastassiades CJ "Nifedipine and beta-blocker drugs." Br Med J 281 (1980): 1251-2. [PMID: 6107167]
8 Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
9 Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
10 Chapple DJ, Clark JS, Hughes R "Interaction between atracurium and drugs used in anaesthesia." Br J Anaesth 55 Suppl 1 (1983): s17-22. [PMID: 6688011]
11 Canadian Pharmacists Association.
12 Dean S, Kendall MJ, Potter S, Thompson MH, Jackson DA "Nadolol in combination with indapamide and xipamide in resistant hypertensives." Eur J Clin Pharmacol 28 (1985): 29-33. [PMID: 3987783]
13 Cass E, Kadar D, Stein HA "Hazards of phenylephrine topical medication in persons taking propranolol." Can Med Assoc J 120 (1979): 1261-2. [PMID: 221086]
14 Asgharnejad M, Powell R, Donn K, Danis M "The effect of cimetidine dose timing on oral propranolol kinetics in adults." Clin Pharmacol Ther 41 (1987): 203. [PMID: 3392231]
15 Chrysant SG "Experience with terazosin administered in combination with other antihypertensive agents." Am J Med 80 (1986): 55-61. [PMID: 2872808]
16 Cerner Multum, Inc. "Australian Product Information.".
17 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
18 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
19 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
20 Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.
21 Bonde J, Bodtker S, Angelo HR, Svedsen TL, Kampmann JP "Atenolol inhibits the elimination of disopyramide." Eur J Clin Pharmacol 28 (1985): 41-3. [PMID: 3987784]
22 Leor J, Levartowsky D, Sharon C, Farfel Z "Amiodarone and beta-adrenergic blockers: an interaction with metoprolol but not with atenolol." Am Heart J 16 (1988): 206-7. [PMID: 3394625]